Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABILIFY vs ALLZITAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Partial agonist at dopamine D2 and serotonin 5-HT1A receptors; antagonist at serotonin 5-HT2A receptors.
Allzital contains phenobarbital, a barbiturate that enhances GABA-A receptor activity by increasing the duration of chloride ion channel opening, leading to neuronal hyperpolarization and inhibition of neurotransmission.
Schizophrenia,Bipolar I disorder (acute manic/mixed episodes, maintenance),Major depressive disorder (adjunctive therapy),Irritability associated with autistic disorder,Tourette's disorder
Sedation,Short-term treatment of insomnia,Management of seizure disorders (generalized tonic-clonic and partial seizures),Preoperative anxiety
Schizophrenia: 10-15 mg once daily (max 30 mg). Bipolar mania: 15-30 mg once daily (as monotherapy or adjunct). Adjunctive MDD: 2-5 mg once daily, titrating to 5-10 mg. Autism irritability: 2 mg/day initially, titrated to 5-10 mg/day (max 15 mg/day).
5-10 mg orally every 4-6 hours as needed for pain; not to exceed 40 mg per day.
Aripiprazole: 75 hours; dehydro-aripiprazole: 94 hours. Steady-state reached in ~14 days.
Terminal elimination half-life is 4-6 hours in healthy adults; prolonged to 8-12 hours in renal impairment.
Hepatic metabolism primarily via CYP3A4 and CYP2D6; also by dehydrogenation and N-dealkylation.
Primarily hepatic via CYP2C9, CYP2C19, and glucuronidation; metabolized to inactive metabolites (e.g., p-hydroxyphenobarbital) that are excreted renally.
Renal (25% unchanged, 18% as dehydro-aripiprazole) and fecal (55% unchanged and metabolites).
Renal: 70% as unchanged drug; biliary/fecal: 20% as metabolites; 10% other.
>99% bound to albumin and alpha-1-acid glycoprotein.
92% bound to albumin and alpha-1-acid glycoprotein.
4.9 L/kg (high distribution into tissues).
2.5-3.5 L/kg; large Vd indicates extensive tissue distribution.
Oral: 87% (tablet and solution); IM: 100%.
Oral: 85-90% due to first-pass metabolism; intravenous: 100%.
No dosage adjustment required for renal impairment; not removed by hemodialysis.
GFR 30-50 m L/min: 50% dose reduction; GFR <30 m L/min: avoid use.
No specific guidelines; use caution in severe hepatic impairment (Child-Pugh class C) due to limited data.
Child-Pugh Class B: 50% dose reduction; Child-Pugh Class C: avoid use.
Schizophrenia (13-17 years): 2 mg/day, target 10-25 mg/day. Bipolar mania (10-17 years): 2 mg/day, target 10-30 mg/day. Autism irritability (6-17 years): 2 mg/day, target 5-15 mg/day.
0.1-0.2 mg/kg orally every 4-6 hours as needed; maximum single dose 5 mg; not to exceed 20 mg per day.
Initiate at lower doses (e.g., 2-5 mg/day) and titrate slowly due to increased risk of adverse effects, especially orthostatic hypotension and cognitive decline.
Initiate at 2.5 mg orally every 6 hours; titrate cautiously due to increased sensitivity and risk of respiratory depression.
Increased risk of death in elderly patients with dementia-related psychosis due to cerebrovascular events.
Risk of respiratory depression, particularly with rapid IV administration or excessive doses; co-administration with CNS depressants (e.g., opioids, alcohol) may exacerbate this effect. Use in pregnancy may cause fetal harm (teratogenic effects).
Increased mortality in elderly dementia patients, suicidal thoughts/behaviors, neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes (hyperglycemia, dyslipidemia, weight gain), orthostatic hypotension, leukopenia/neutropenia, seizures, body temperature dysregulation, dysphagia, impulse control disorders.
Respiratory depression, CNS depression, dependence and withdrawal (taper gradually), paradoxical excitation (especially in elderly), use in hepatic or renal impairment, drug interactions with warfarin, oral contraceptives, and corticosteroids.
Known hypersensitivity to aripiprazole or any of its excipients.
Hypersensitivity to barbiturates, severe respiratory insufficiency, history of porphyria, severe hepatic impairment, pregnancy (especially first trimester).
Grapefruit juice may increase aripiprazole exposure; avoid concurrent intake. No other significant food interactions. Alcohol can enhance CNS depression; limit or avoid.
Avoid excessive alcohol consumption; may increase hepatotoxicity. No significant food interactions. Take with or without food; food may reduce GI upset.
Pregnancy category C. First trimester: risk of major malformations not significantly increased based on limited data; however, neurodevelopmental effects uncertain. Second and third trimesters: neonates exposed in late pregnancy are at risk for extrapyramidal symptoms (EPS) and withdrawal syndrome including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorder.
Allzital (butalbital/acetaminophen/caffeine) is category C. First trimester: risk of neural tube defects increased with barbiturate exposure; avoid. Second/third trimester: barbiturate use may lead to neonatal withdrawal and coagulation defects due to vitamin K deficiency; use only if benefit outweighs risk.
Aripiprazole is excreted in human breast milk; milk-to-plasma (M/P) ratio is approximately 0.5 to 1.0. Relative infant dose is estimated to be 1-3% of maternal weight-adjusted dose. Limited data; use with caution. Monitor infant for sedation, poor feeding, and abnormal movements.
Butalbital and acetaminophen are excreted into breast milk in low amounts. Caffeine also enters milk. M/P ratio not established for butalbital. Use caution; monitor infant for sedation, poor feeding. American Academy of Pediatrics considers butalbital compatible with breastfeeding but avoid prolonged use.
No established pharmacokinetic data; however, pregnancy-induced physiological changes (increased plasma volume, renal clearance) may lower aripiprazole levels. Monitor therapeutic efficacy and consider dose adjustment if symptom exacerbation. No specific dose modification guidelines available; titrate based on clinical response and tolerability.
No specific dose adjustments established for pregnancy. Pharmacokinetic changes (increased volume of distribution, hepatic metabolism) may reduce butalbital levels; clinical efficacy not well studied. Use lowest effective dose shortest duration. Acetaminophen doses remain standard (<4 g/day). Avoid caffeine >300 mg/day.
Abilify (aripiprazole) is a partial dopamine agonist, which reduces the risk of extrapyramidal symptoms and hyperprolactinemia compared to full antagonists. Monitor for akathisia, especially during dose titration. QT prolongation risk is lower than with other antipsychotics; use caution in patients with cardiac disease. Avoid use in dementia-related psychosis due to increased mortality. Therapeutic effects may take 2-4 weeks; full response often requires 6-8 weeks.
ALLZITAL is a combination analgesic containing acetaminophen and tramadol. Monitor for serotonin syndrome when used with other serotonergic drugs. Avoid in patients with severe hepatic impairment or acute alcohol intoxication. Maximum daily acetaminophen dose is 4000 mg; reduce in hepatic risk. Tramadol may lower seizure threshold; use cautiously in epilepsy. Not recommended in breastfeeding due to tramadol excretion. Adjust dose in renal impairment (Cr Cl <30 m L/min: extended interval). Discontinue gradually to avoid withdrawal.
Take exactly as prescribed; do not stop abruptly without consulting your doctor.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Avoid alcohol and grapefruit juice as they can alter drug levels.,Report any uncontrolled muscle movements, especially in face or tongue.,Monitor weight and blood glucose regularly as it can cause metabolic changes.,If you miss a dose, take it as soon as you remember unless it's almost time for the next dose; do not double up.,Use effective contraception if of childbearing potential; discuss pregnancy plans with your doctor.
Do not exceed 8 tablets per day due to acetaminophen liver risk.,Avoid alcohol and other acetaminophen-containing products.,May cause dizziness or drowsiness; avoid driving until effect known.,Report signs of serotonin syndrome (agitation, hallucinations, rapid heart rate).,Do not stop suddenly; taper to prevent withdrawal symptoms.,Store at room temperature away from moisture.,Use only as prescribed; risk of dependence with tramadol.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABILIFY vs ALLZITAL, answered by our medical review team.
ABILIFY is a Atypical antipsychotic that works by Partial agonist at dopamine D2 and serotonin 5-HT1A receptors; antagonist at serotonin 5-HT2A receptors.. ALLZITAL is a Barbiturate Analgesic Combination that works by Allzital contains phenobarbital, a barbiturate that enhances GABA-A receptor activity by increasing the duration of chloride ion channel opening, leading to neuronal hyperpolarization and inhibition of neurotransmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABILIFY and ALLZITAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABILIFY is: Schizophrenia: 10-15 mg once daily (max 30 mg). Bipolar mania: 15-30 mg once daily (as monotherapy or adjunct). Adjunctive MDD: 2-5 mg once daily, titrating to 5-10 mg. Autism irritability: 2 mg/day initially, titrated to 5-10 mg/day (max 15 mg/day).. The standard adult dose of ALLZITAL is: 5-10 mg orally every 4-6 hours as needed for pain; not to exceed 40 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABILIFY and ALLZITAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABILIFY is classified as Category C. Pregnancy category C. First trimester: risk of major malformations not significantly increased based on limited data; however, neurodevelopmental effects uncertain. Second and thir. ALLZITAL is classified as Category C. Allzital (butalbital/acetaminophen/caffeine) is category C. First trimester: risk of neural tube defects increased with barbiturate exposure; avoid. Second/third trimester: barbitu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.